Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Brain Cancer treatment details. Biologic therapy. Brigham and Women's Hospital, Boston, MA, United States

Survival: 2.6 months
Toxicity Grade: 3
Treatments: Biologic therapy
Country: United States
City/State/Province: Boston, MA
Hospital: Brigham and Women's Hospital
Journal: Link
Date: 1/2015

This phase 2 study involved high-grade glioma (glioblastoma or anaplastic glioma) patients who were divided into groups based on prior treatment. Group A consisted of 22 patients who had not received prior bevacizumab treatment; the median patient age was 54 years and 7 were male. Group B consisted of 14 patients who had been previously treated with bevacizumab; the median age was 52 years and 11 were male.

Patients in groups A and B received biologic therapy with nintedanib, an inhibitor of multiple tyrosine kinases.

There were two treatment-related deaths in group A due to pulmonary embolism and colonic perforation. Grade 2 high blood pressure was also reported.

The most severe toxicities in group B were of grade 3 and included abdominal pain and high blood pressure. Grade 2 fatigue and nausea were also reported.

The median overall survival in groups A and B was 6.9 and 2.6 months, respectively.

Correspondence: Dr. Andrew D. Norden; email:

E-mail to a Friend Email Physician More Information